AU2021407023B2 - Anti-b7-h3 antibody and uses thereof - Google Patents

Anti-b7-h3 antibody and uses thereof

Info

Publication number
AU2021407023B2
AU2021407023B2 AU2021407023A AU2021407023A AU2021407023B2 AU 2021407023 B2 AU2021407023 B2 AU 2021407023B2 AU 2021407023 A AU2021407023 A AU 2021407023A AU 2021407023 A AU2021407023 A AU 2021407023A AU 2021407023 B2 AU2021407023 B2 AU 2021407023B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
antibody
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021407023A
Other languages
English (en)
Other versions
AU2021407023A1 (en
Inventor
Fenggen FU
Li Li
Haiqing NI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fortvita Biologics (Singapore) Pte Ltd
Original Assignee
Fortvita Biologics (Singapore) Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fortvita Biologics (Singapore) Pte Ltd filed Critical Fortvita Biologics (Singapore) Pte Ltd
Publication of AU2021407023A1 publication Critical patent/AU2021407023A1/en
Assigned to INNOVENT BIOLOGICS (SINGAPORE) PTE. LTD. reassignment INNOVENT BIOLOGICS (SINGAPORE) PTE. LTD. Request for Assignment Assignors: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
Assigned to Fortvita Biologics (Singapore) Pte.Ltd. reassignment Fortvita Biologics (Singapore) Pte.Ltd. Amend patent request/document other than specification (104) Assignors: INNOVENT BIOLOGICS (SINGAPORE) PTE. LTD.
Application granted granted Critical
Publication of AU2021407023B2 publication Critical patent/AU2021407023B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021407023A 2020-12-23 2021-12-22 Anti-b7-h3 antibody and uses thereof Active AU2021407023B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011544445 2020-12-23
CN202011544445.8 2020-12-23
PCT/CN2021/140449 WO2022135467A1 (zh) 2020-12-23 2021-12-22 抗b7-h3抗体及其用途

Publications (2)

Publication Number Publication Date
AU2021407023A1 AU2021407023A1 (en) 2023-07-20
AU2021407023B2 true AU2021407023B2 (en) 2025-12-04

Family

ID=82157408

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021407023A Active AU2021407023B2 (en) 2020-12-23 2021-12-22 Anti-b7-h3 antibody and uses thereof

Country Status (8)

Country Link
US (1) US20240043540A1 (cg-RX-API-DMAC7.html)
EP (1) EP4269435A4 (cg-RX-API-DMAC7.html)
JP (1) JP7871265B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230124959A (cg-RX-API-DMAC7.html)
CN (1) CN117098548A (cg-RX-API-DMAC7.html)
AU (1) AU2021407023B2 (cg-RX-API-DMAC7.html)
CA (1) CA3203257A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022135467A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119948063A (zh) * 2022-06-23 2025-05-06 信达生物制药(苏州)有限公司 结合egfr和b7-h3的双特异性抗体
WO2024007129A1 (zh) * 2022-07-04 2024-01-11 英诺湖医药(杭州)有限公司 人源化的b7h3抗体或其抗原结合片段
CN119925631A (zh) * 2023-11-03 2025-05-06 信达生物制药(苏州)有限公司 靶向b7-h3的抗体-药物偶联物及其用途
WO2025131054A1 (en) * 2023-12-22 2025-06-26 Innovent Biologics (Suzhou) Co., Ltd. Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170240637A1 (en) * 2014-08-27 2017-08-24 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
DK2542256T3 (da) * 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2703486B1 (en) * 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
US10865245B2 (en) * 2014-12-23 2020-12-15 Full Spectrum Genetics, Inc. Anti-B7H3 binding compounds and uses thereof
RS61828B1 (sr) * 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
CN109843927B (zh) * 2017-03-06 2022-06-21 江苏恒瑞医药股份有限公司 抗b7-h3抗体、其抗原结合片段及其医药用途
TW201909926A (zh) * 2017-08-04 2019-03-16 大陸商江蘇恆瑞醫藥股份有限公司 B7h3抗體-藥物偶聯物及其醫藥用途
WO2020094120A1 (zh) * 2018-11-09 2020-05-14 上海复旦张江生物医药股份有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN109851673B (zh) * 2019-01-22 2023-07-25 苏州旭光科星抗体生物科技有限公司 一种抗人b7-h3单克隆抗体的制备方法及其免疫组化检测方法及其应用及其试剂盒
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170240637A1 (en) * 2014-08-27 2017-08-24 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses

Also Published As

Publication number Publication date
AU2021407023A1 (en) 2023-07-20
JP7871265B2 (ja) 2026-06-08
EP4269435A1 (en) 2023-11-01
EP4269435A4 (en) 2025-06-18
CN117098548A (zh) 2023-11-21
JP2024500512A (ja) 2024-01-09
WO2022135467A1 (zh) 2022-06-30
US20240043540A1 (en) 2024-02-08
KR20230124959A (ko) 2023-08-28
CA3203257A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
AU2019219312B2 (en) C-kit antibodies
KR102389083B1 (ko) 항-cd47 항체 및 그 용도
KR102540192B1 (ko) Cd123 결합제 및 그의 용도
EP4169947A1 (en) Anti-claudin18.2 antibody and use thereof
US8461304B2 (en) Antibodies
EP3838289A1 (en) Anti-tigit antibody and uses thereof
KR20210109520A (ko) 항체 및 이의 용도
KR20200139725A (ko) Her3 항원 결합 분자
EP4269435A1 (en) Anti-b7-h3 antibody and uses thereof
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
CN111065652A (zh) 抗4-1bb抗体、其抗原结合片段及其医药用途
WO2008117049A1 (en) Human anti cd166 antibody binding human tumor cells
EP4223778A1 (en) Anti-claudin18.2 and cd3 bispecific antibody and use thereof
KR20230110523A (ko) 델타-유사 리간드 3(dll3) 항원 결합 영역을 포함하는 단백질 및 그의 용도
WO2022166876A1 (zh) 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
KR20160010391A (ko) Cd20 및 cd95에 결합하는 재조합 이중특이성 항체
US20240067747A1 (en) Cd73-binding protein and use thereof
EP4289865A1 (en) Anti-tnfr2 antibody and use thereof
CN114316045B (zh) 抗pd-l1抗体及其用途
EP4624492A1 (en) Anti-ccr8 antibody and use thereof
EP4382538A1 (en) Anti-cd79b×cd3 bispecific antibody and use thereof
KR20230169942A (ko) 항-pd-l1 항체 및 이의 용도
US20240254227A1 (en) Anti-CD300LB Antibodies and Methods of Use Thereof
WO2025067442A1 (zh) 抗fgfr2抗体和包含其的多特异性结合分子
HK40075856A (en) Her3 antigen-binding molecules

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: INNOVENT BIOLOGICS (SINGAPORE) PTE. LTD.

Free format text: FORMER APPLICANT(S): INNOVENT BIOLOGICS (SUZHOU) CO., LTD.

HB Alteration of name in register

Owner name: FORTVITA BIOLOGICS (SINGAPORE) PTE.LTD.

Free format text: FORMER NAME(S): INNOVENT BIOLOGICS (SINGAPORE) PTE. LTD.

FGA Letters patent sealed or granted (standard patent)